Tsukasa Aihara

Dr. Tsukasa Aihara

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
TNTakayoshi Nakajima
Takayoshi Nakajima
SIShinichi Ikuta
Shinichi Ikuta
MFMasataka Fujikawa
Masataka Fujikawa
LILisa Ikuta
Lisa Ikuta
GMGoshi Matsuki
Goshi Matsuki
NYNaoki Yamanaka
Naoki Yamanaka


21 October 2024 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
TNTakayoshi Nakajima
Takayoshi Nakajima
SIShinichi Ikuta
Shinichi Ikuta
TATsukasa Aihara
Tsukasa Aihara
LILisa Ikuta
Lisa Ikuta
GMGoshi Matsuki
Goshi Matsuki
NYNaoki Yamanaka
Naoki Yamanaka

1 November 2020 in The Japanese Journal of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
TNTakayoshi Nakajima
Takayoshi Nakajima
SIShinichi Ikuta
Shinichi Ikuta
NINoriko Ichise
Noriko Ichise
MKMeidai Kasai
Meidai Kasai
IHIkumi Hamano
Ikumi Hamano
NYNaoki Yamanaka
Naoki Yamanaka
症例は73歳の女性で,上腹部痛を契機に認められた4.5 cm大の肝内胆管癌(intrahepatic cholangiocarcinoma;以下,ICCと略記)を疑って肝右3区域切除術を施行,中分化型の腫瘤形成型ICCと診断された.再肝部分切除術は,①初回術後2年1か月,肝S1の2 cm大の単発再発,②初回術後2年9か月,肝S1の3 cm大の単発再発,③初回術後3年8か月,肝S2の1.5 cm大の単発再発,④初回術後5年9か月,肝S3の2 cm大の単発再発,⑤初回術後6年11か月,肝S2に3 cm大の単発再発,に対して行った.再切除した腫瘍はいずれも中分化型の腫瘤形成型ICCの所見で被膜浸潤および脈管侵襲を認めなかった.現在,初回手術後12年以上経過したが無再発生存中である.ICC切除例として希少な症例と考えられ報告する.

20 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TATsukasa Aihara
Tsukasa Aihara
SIShinichi Ikuta
Shinichi Ikuta
TNTakayoshi Nakajima
Takayoshi Nakajima
SNShinta Nagano
Shinta Nagano
TIToshimitsu Iwasaki
Toshimitsu Iwasaki
NYNaoki Yamanaka
Naoki Yamanaka
Introduction: Radical hepatectomy is the standard curative treatment for colorectal liver metastases (CRLMs). However, extensive resection may be contraindicated in patients with insufficient liver reserve or anatomically complex disease. Although ablation therapy is generally not recommended as a primary curative modality in current guidelines, intraoperative ablation may facilitate parenchymal-sparing, curative-intent treatment in selected high-risk patients. Methods: This retrospective cohort study included 118 patients who underwent curative-intent hepatectomy for multiple CRLM. Patients were categorized into hepatectomy-only (Hx) and hepatectomy plus intraoperative ablation (Hx + Abl) groups, and propensity score matching (PSM) generated 29 balanced pairs. Overall survival (OS) and hepatic progression-free survival (HPFS) were compared using a log-rank test. Cox regression identified predictors of OS, and receiver operating characteristic (ROC) analysis evaluated tumor size associated with local recurrence after ablation. Results: Before PSM, the HX + Abl group showed higher tumor burden and Beppu scores, and demonstrated inferior OS and HPFS. After PSM, oncological outcomes were comparable. Perioperative outcomes, including major complications and post-hepatectomy liver failure (PHLF), were similar. Preoperative chemotherapy was an independent predictor of OS. Among 99 ablated tumors, local recurrence occurred in 12 lesions, and ROC analysis identified tumor size ≤ 15mm as the optimal cutoff predicting local recurrence. Conclusions: In selected high-risk CRLM patients, hepatectomy with intraoperative ablation had no statistically significant difference in OS and HPFS compared with hepatectomy alone without increasing major complications or PHLF.

12 August 2024 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
SIShinichi Ikuta
Shinichi Ikuta
TATsukasa Aihara
Tsukasa Aihara
MKMeidai Kasai
Meidai Kasai
TNTakayoshi Nakajima
Takayoshi Nakajima
NYNaoki Yamanaka
Naoki Yamanaka
Shinichi Ikuta, Tsukasa Aihara, Meidai Kasai, Takayoshi Nakajima, Naoki Yamanaka. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.24-110